CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, ...
The use of Artificial Intelligence (AI) and Machine Learning (ML) in clinical research is rapidly evolving, offering a glimpse into a future where medical innovation is driven by data-driven ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A St. Louis private equity firm ...
The new CTO-H provides the largest, longest and deepest view of hematological diseases ever created — establishing a new standard for clinical research Starting in 2023, NeoGenomics and ConcertAI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results